Table 2.
Natural transmission dose based on contact exposure studies before Fel-O-Vax® FIV release in the respective countries a.
| Trial/Study b (Reference) | Type of Contact Exposure | Years of Contact Exposure | Transmission Rate (%) | Transmission Dose (CID50) c | FIV Donor Subtype | Subtype Prevalent in Country d (References) |
|---|---|---|---|---|---|---|
| Italy [47] 2000 |
Free roaming (field FIV+ cats) |
1 1.5–1.8 |
2/14 (14%) 5/14 (36%) |
0.29 0.72 |
Subtype B | Subtype B [24,57] |
| Japan [51] 2005 |
Closed housing e (FIVAo2-infected males) |
1 1.5 |
3/8 (37%) 4/8 (50%) |
0.75 1.00 |
Subtype B (FIVAo2) e |
Subtypes B, A, D [58] |
| U.S. [33] 1988 |
Closed housing f (Mixed-sex field FIV+ cats from CA & HI) |
1 1.75 2.5 |
1/3 (33%) 2/3 (67%) 3/3 (100%) |
0.67 1.33 2.00 |
Subtype A Subtype B |
Subtypes B, A [24] |
| Combined Studies | - | 1 1.5–1.8 2.5 |
6/25 (24%) 11/25 (44%) 3/3 (100%) |
0.48 0.88 2.00 |
Subtype A Subtype B |
a Table adapted from reference [33]. b Contact exposure trials in three countries shown with either the publication date of the trial (Italy, Japan) or the start date of the study (U.S.) were performed before Fel-O-Vax® FIV release in the respective countries. c Mean (50%) cat infectious dose (CID50). d Subtypes in the order of prevalence in the country. e FIVAo2-infected male cats were housed with FIV-naïve male cats.